Article history: Received 29 June 2017 Received in revised form 4 September 2017 Accepted 5 September 2017 A model was made for prediction of the trajectory of an irregularly shaped body moving through a resistive medium with high velocities, using data for aerodynamic forces obtained from numerical simulations. For a different orientation of the body with respect to the velocity vector of the center of mass, the aerodynamic resistance force is different for two reasons: the exposed surface area is different and the shape is different. In this regard, 216 numerical simulations of airflow around of the body of an irregularly shaped body in different orientations were carried out, for one full rotation (around one axis of rotation) of the body, with angular increments of 15 (0 360), for the following velocities: 0.6, 0.8, 1, 1.2, 1.3, 1.5, 2, 3 and 4 Mach. The outcome of these simulations is the resistance forces and aerodynamic moments as the result of motion of the body in various directions relatively to the body. After the simulations had been performed, the results of the resistance forces and aerodynamic moments were used to integrate the equations of motion with an assumption that the irregularly shaped body had a continuous rotation all the way along the trajectory with relatively high angular velocities. With this assumption, an effective aerodynamic force was calculated which takes into consideration that the aerodynamic force varies due to the rotation of the body. The results show that the trajectory of an irregularly shaped body is curved in space because the side component of the aerodynamic force cannot be ignored because of the irregular shape of the body, which leads to significant lateral movement of the body from the initial direction of flight.

OBJECTIVE The aim was to study the association of the use of an oral antihyperglycemic agent metformin with the presence of ocular complications in patients with type 2 diabetes (T2D). METHODS Medical records were reviewed for 234 patients with diagnosed T2D. 81.2% (n=190) patients were using metformin and 18.8% (n=44) using other oral antihyperglycemic agents. Plasma glucose concentration, glycated haemoglobin, and the presence of ocular complications in patients treated with metformin were compared to those in patients treated with other oral antihyperglycemic agents. RESULTS Ocular complications occurred in 65 patients (27.8%). Patients treated with metformin had fewer ocular complications compared to patients treated with other oral antihyperglycemic agents (χ2=19.985; p<0.0001). After adjustment for gender, age, duration of T2D, serum concentration of cholesterol, smoking, body mass index and presence of other diseases, treatment with metformin decreased the odds of both glaucoma (OR=0.14, 95% CI: 0.03-0.57, p=0.006) and diabetic retinopathy (OR=0.33, 95% CI: 0.14-0.82, p=0.017) compared with other oral antihyperglycemic agents. CONCLUSION Our results suggest that metformin may have a protective effect on ocular complications, especially glaucoma, in patients with T2D. The effects of metformin either regarding prevention of ocular complications or ocular complications already developed in patients with T2D, should be further investigated.